An NCI-designated Comprehensive Cancer Center

Yuan Yuan, M.D., Ph.D.

Medical Oncologist
Clinical Expertise
Research Focus
  • Breast Cancer Research
  • Triple Negative Breast Cancer
Appointments
Associate Professor, Department of Medical Oncology & Therapeutics Research
Contact
Email: [email protected]
Other Languages Spoken
  • Mandarin

Clinical Teams

Yuan Yuan, M.D., Ph.D. is an Associate Professor specializing in breast oncology in the Department of Medical Oncology & Therapeutics.

Prior to joining City of Hope in 2012, she was an assistant professor at Loma Linda University Medical Center in the Division of Medical Oncology and Hematology, and a principal investigator for multiple breast cancer trials. Dr. Yuan received her bachelor of medicine degree from Xuzhou Medical College in Xuzhou, China, and an M.S. in oncology from Peking Union Medical College in Beijing, China. She went on to complete a Ph.D. in biochemistry and molecular biology from the University of California, Riverside. She then completed a research fellowship at the Scripps Research Institute in La Jolla, CA, followed by an internship and residency in internal medicine at the New York University Downtown Hospital in New York, NY. She furthered her training with a hematology and oncology fellowship at the New York University Medical Center, under the direction of Dr. Franco Muggia.

Dr. Yuan’s clinical research interests center on novel therapeutics for metastatic triple negative breast cancer (TNBC). She currently leads multiple clinical trials for metastatic triple negative breast cancer including the following targeted therapies: immune check point inhibitors, androgen receptor targeted therapy, PIK3CA pathway inhibition. She is awarded a STOP CANCER Career Development Award supporting translational research in TNBC tumor evolution and a NIH R03 grant studying biomarkers predicting chemotherapy toxicity in women with breast cancer undergoing chemotherapy. She is experienced in pre-clinical, translational, and clinical application of novel combination therapies. She has worked closely with City of Hope’s translational scientist, molecular pathology core, genomics, bioinformatics and biostatistics core to study the longitudinal genomic mutation profiling of paired metastatic breast cancer. She serves as principle investigator for multiple investigator-initiated trials including a phase II trial combining letrozole, palbociclib and pembrolizumab in patients with HR+ metastatic BC (NCT02778685); a phase I/IB clinical trial studying eribulin plus everolimus in patients with metastatic TNBC (NCT02120469); a phase II trial androgen receptor (AR) targeted therapy GTx-024 in combination with pembrolizumab in patients with metastatic AR+ TNBC; a phase IB study combining ipatasertib with carboplatin or carboplatin/paclitaxel in patients with metastatic TNBC. Her clinical trial work in AR+ TNBC was awarded Phase I Foundation Grant in correlative studies.

Dr. Yuan has multiple publications in peer-reviewed literature and has been invited to present at national and international meetings. She is board certified in internal medicine, hematology and oncology.

Locations

City of Hope Comprehensive Cancer Center, 1500 East Duarte Road

Duarte, CA 91010

Afkhami M, Schmolze D, Yost SE, Frankel PH, Dagis A, Amanam IU, Telatar M, Nguyen K, Yu KW, Luu T, Pillai R, Aoun PA, Mortimer J, Yuan Y. Mutation and Immune Profiling of Metaplastic Breast Cancer: Correlation with Survival. PLoS One. 2019 Nov 6;14(11):e0224726. doi: 10.1371/journal.pone.0224726. eCollection 2019. PubMed [journal] PMID: 31693690
 
Lee JS, Yost SE, Blanchard S, Schmolze D, Yin HH, Pillai R, Robinson K, Tang A, Martinez N, Portnow J, Wen W, Yim JH, Brauer HA, Ren Y, Luu T, Mortimer J, Yuan Y. Phase I Clinical Trial of the Combination of Eribulin and Everolimus in Patients with Metastatic Triple Negative Breast Cancer.   Breast Cancer Research. 2019 Nov 8;21(1):119. doi: 10.1186/s13058-019-1202-4. PubMed [journal] PMID: 31703728
 
J.E. Mortimer, L. Kruper, J. Jung, L. Wong, J. Cooper, D. Stewart, S. Chung, K.W. Yu, S. Dadwal, Y. Yuan.  Characterization of Infections and Hypogammaglobulinemia Treated with the Combination of Pertuzumab and Trastuzumab.  Cancer Chemotherapy and Pharmacology.  2019 Oct 23.  doi: 10.1007/s00280-019-03970-8. PubMed [journal] PMID: 31641845
 
Hutchinson KE, Yost SE, Chang CW, Johnson RM, Carr AR, McAdam PR, Halligan DL, Chang CC, Schmolze D, Liang J, Yuan Y. Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts. Clin Cancer Res. 2019 Oct 14. doi: 10.1158/1078-0432.CCR-19-1773. [Epub ahead of print] PubMed [journal] PMID: 31611282
 
Egelston CA, Avalos C, Tu TY, Rosario A, Wang R, Solomon S, Srinivasan G, Nelson MS, Huang Y, Lim MH, Simons DL, He TF, Yim JH, Kruper L, Mortimer J, Yost S, Guo W, Ruel C, Frankel PH, Yuan Y, Lee PP.  Resident Memory CD8+ T Cells within Cancer Islands Mediate Survival in Breast Cancer Patients. JCI Insight. 2019 Oct 3;4(19). PubMed [journal] PMID: 31465302
 
Yuan Y H, Yost S, Blanchard S, Yin H, Li M, Robinson K, Tang A, Martinez N, Leong L, Somlo G, Tank Patel N, Waisman J, Portnow J, Hurria A, Luu T-h, Mortimer J. Phase I Trial of Eribulin and Everolimus in Patients with Metastatic Triple Negative Breast Cancer. Breast Cancer Res, 21 (1) 119. 2019 Nov 8. Doi: 10.1186/s13058-019-1202-4 PubMed [journal]  PMID: 31703728 PMCID: PMC6839083
 
Chen BT, Ye N, Wong CW, Patel SK, Jin T, Sun CL, Rockne RC, Kim H, Root JC, Saykin AJ, Ahles TA, Holodny Al, Prakash N, Mortimer J, Sedrak MS, Waisman J, Yuan Y et al.  Effects of Chemotherapy on Aging White Matter Microstructure: a Longitudinal Diffusion Tensor Imaging Study. J Geriatr Oncol.  2019 Nov 2. pii: S1879-4068(19)30166-3. doi: 10.1016/j.jgo.2019.09.016. PubMed [journal] PMID: 31685415
 
Schmolze D., Afkhami M., Yost S., Yuan Y et al. Mutational and Immune Profiling of Metaplastic Breast Cancer: Correlation with Survival. January 2018 USCAP. PLoS One, 14 (11), e0224726, 2019 Nov 6, eCollection 2019.  Doi: 10.1371/journal.pone.0224726.  PMID: 31693690  PubMed [journal] PMCID: PMC6834262
 
Chen BT, Jin T, Patel SK, Ye N, Ma H, Wong CW, Rockne RC, Root JC, Saykin AJ, Ahles TA, Holodny AI, Prakash N, Mortimer J, Waisman J, Yuan Y, Li D, Sedrak MS, Vazquez J, Katheria V, Dale W. McQuerry JA, Jenkins DF, Yost SE, Zhang Y, Schmolze D, Johnson WE, Yuan Y, Bild AH. Pathway Activity Profiling of Growth Factor Receptor Network and Stemness Pathways Differentiates Metaplastic Breast Cancer Histological Subtypes. BMC Cancer. 2019 Sep 5;19(1):881. PubMed [journal] PMID: 31488082
 
Intrinsic Brain Activity C with Adjuvant Chemotherapy in Older Women with Breast Cancer: A Pilot Longitudinal Study. Breast Cancer Res Treat. 2019 July; 176(1): 181-189. PubMed [journal] PMID: 30989462
 
Lin FM, Yost SE, Wen W, Frankel PH, Schmolze D, Chu PG, Yuan YC, Liu Z, Yim J, Chen Z, Yuan Y. Differential Gene Expression and AKT Targeting in Triple Negative Breast Cancer. Oncotarget. July 2019; 10(43): 4356-4368. PubMed [journal] PMID: 31320990
 
Wen W, Marcinkowski E, Luyimbazi D, Luu T, Xing Q, Yan J, Wang Y, Wu J, Guo Y, Tully D, Han ES, Yost SE, Yuan Y, Yim JH. Eribulin Synergistically Increases Anti-Tumor Activity of mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer. Cells. 2019 Aug 30;8(9). pii: E1010. PubMed [journal] PMID: 31480338
 
Marcinkowski E, Luu T, Yuan Y, Mortimer J, Leong L, Portnow J, Xing Q, Wen W, Yim J. The Combination of Eribulin and Everolimus Results in Enhanced Suppression of Tumors in Mouse Models of Triple Negative Breast Cancer. Cells, 8 (9) 2019 Aug 30. Doi: 10.3390/cells8031010 PubMed [journal] PMID: 31480338 PMCID: PMC6770784
 
Yuan Y, Wen W, Yost SE, Xing Q, Yan J, Han ES, Mortimer J, Yim JH; Combination therapy with BYL719 and LEE011 is Synergistic and Causes a Greater Suppression of p-S6 in Triple Negative Breast Cancer. Sci Rep. 2019 May 17; 9(1):7509. PubMed [journal] PMID: 31101835
 
Chung V, Kos FJ, Hardwick N, Yuan Y, Chao J, Li D, Waisman J, Li M, Zurcher K, Frankel P, Diamond DJ. Evaluation of Safety and Efficacy of p53MVA Vaccine Combined with Pembrolizumab in Patients with Advanced Solid Cancers. Clinical and Translational Oncology. 2019 Mar; 21(3):363-372. PubMed [journal] PMID: 30094792
 
Zhao ZM, Yost SE,  Hutchinson KE, Li SM, Yuan YC., Noorbakhsh J, Liu Z, Warden C, Johnson RM, Wu X, Chuang JH, Yuan Y. CCNE1 Amplification is Associated with Poor Prognosis in Patients with Triple Negative Breast Cancer. BMC Cancer. 2019 Jan 21;19(1):96. PubMed [journal] PMID: 30665374 PMCID: PMC6341717
 
Ding YC, Steele L, Warden C, Wilczynski S, Mortimer J, Yuan Y, Neuhausen SL. Molecular Subtypes of Triple-Negative Breast Cancer in Women of Different Race and Ethnicity. Oncotarget. 2019 Jan 4;10(2):198-208. PubMed [journal] PMID: 30719214
 
Chen BT, Ghassaban K, Jin T, Patel SK, Ye N, Sun CL, Kim H, Rockne RC, Mark Haacke E, Root JC, Saykin AJ, Ahles T, Holodny AI, Prakash N, Mortimer J, Waisman J, Yuan Y, Somlo G, Li D, Yang R, Tan H, Katheria V, Morrison R, Hurria A. Subcortical Brain Iron Deposition and Cognitive Performance in Older Women with Breast Cancer Receiving Adjuvant Chemotherapy: A Pilot MRI Study. Magnetic Resonance Imaging. 2018 Dec; 54:218-224. PubMed [journal] PMID: 30076946 PMCID: PMC6298788
 
Michelle Afkhami, M.D.; Daniel Benedict Schmolze, M.D.; Susan Yost, Ph.D.; Paul Frankel, Ph.D.; Andrew Dagis, M.S.; Idoroenyi Amanam, M.D.; Milhan Telatar, Ph.D.; Kim Nguyen, Pharm.D.; Kim Wai Yu, Pharm.D.; Thehang Luu, M.D.; Raju Pillai, M.D.; Patricia Aoun, M.D.; Joanne Mortimer, M.D.; Yuan Yuan, M.D., Ph.D.; Mutation and Immune Profiling of Metaplastic Breast Cancer: Correlation with Survival. Breast Cancer Research PLoS One. 2019 Nov 6;14(11):e0224726. doi: 10.1371/journal.pone.0224726. eCollection 2019. PubMed [journal] PMID: 31693690 PMCID: PMC683462
 
Chen BT, Jin T, Patel SK, Ye N, Sun CL, Ma H, Rockne RC, Root JC, Saykin AJ, Ahles TA, Holodny AI, Prakash N, Mortimer J, Waisman J, Yuan Y, Li D, Somlo G, Vazquez J, Levi A, Tan H, Yang R, Katheria V, Hurria A. Gray Matter Density Reduction Associated with Adjuvant Chemotherapy in Older Women with Breast Cancer. Breast Cancer Research Treatment. 2018 Nov; 172 (2):363-370. PubMed [journal] PMID: 30088178 PMCID: PMC6208903
 
Hurria A, Soto-Perez-de-Celis E, Blanchard S, Burhenn P, Yeon CH, Yuan Y, Li D, Katheria V, Waisman JR, Luu TH, Somlo G, Noonan AM, Lee T, Sudan N, Chung S, Rotter A, Arsenyan A, Levi A, Choi J, Rubalcava A, Morrison R, Mortimer JE. A Phase II Trial of Older Adults With Metastatic Breast Cancer Receiving nab-Paclitaxel: Melding the Fields of Geriatrics and Oncology. Clinical Breast Cancer. 2018 Oct 16. pii: S1526-8209(18)30328-8. PubMed [journal] PMID: 30503309
 
Blenman KR, He TF, Frankel PH, Ruel NH, Schwartz EJ, Krag DN, Tan LK, Yim JH, Mortimer JE, Yuan Y, Lee PP. Sentinel Lymph Node B Cells Can predict Disease-Free Survival in Breast Cancer Patients. NPJ Breast Cancer. 2018 Aug 23; 4(1):28. PubMed [journal] PMID: 30155518, PMCID: PMC6107630
 
Petrossian K, Kanaya N, Lo C, Hsu PY, Nguyen D, Yang L, Yang L, Warden C, Wu X, Pillai R, Bernal L. Huang CS, Kruper L, Yuan Y, Somlo G, Mortimer J, Chen S. ERα-Mediated Cell Cycle Progression is an Important Requisite for CDK4/6 Inhibitor Response in HR+ Breast Cancer. Oncotarget. 2018 Jun 12;9(45):27736. PubMed [journal] PMID: 29963233, PMCID: PMC6021239
 
Soto-Perez-de-Celis E, Li D, Yuan Y, Lau YM, Hurria A. Functional Versus Chronological Age: Geriatric Assessments to Guide Decision Making in Older Patients with cancer. Lancet Oncol. 2018 Jun; 19(6):e305-e316. PubMed [journal] PMID: 29893262
 
Chen BT, Sethi SK, Jin T, Patel SK, Ye N, Sun CL, Rockne RC, Haacke EM, Root JC, Saykin AJ, Ahles TA, Holodny AI, Prakash N, Mortimer J, Waisman J, Yuan Y, Somlo G, Li D, Yang R, Tan H, Katheria V, Morrison R, Hurria A. Assessing Brain Volume Changes in Older Women with Breast Cancer Receiving Adjuvant Chemotherapy: a Brain Magnetic Resonance Imaging Pilot Study. Breast Cancer Res. 2018 May 2;20(1):38. PubMed [journal] PMID: 29720224, PMCID: PMC5932862
 
Gong J, Cho M, Yu KW, Waisman J, Yuan Y, Mortimer J.  A Single Institution Experience with Palbociclib Requiring Dose Modifications. Breast Cancer Res Treat. 2018 Apr; 168(2):381-387. PubMed [journal] PMID: 29218462, PMCID: PMC5838140
 
Wang T.Y., Fahrmann J.F., Lee H., Li Y.J., Tripathi S.C., Yue C., Zhang C., Lifshitz V., Song J., Jandial R., Yuan Y, Somlo G., Ann D., Hanash S., Jove R., Yu H.; JAK/STAT3-Regulated Fatty Acid β-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance. Cell Metabolism. Cell Metabolism. 2018 Jan 9; 27 (1):136-150. PubMed [journal] PMID: 29249690, PMCID: PMC5777338
 
Yuan Y, Vora N, Sun CL, Li D, Smith D, Mortimer J, Luu TH, Somlo G, Waisman J, Chao J, Katheria V, Synold T, Tran V, Mi S, Feng T, Levi A, Arsenyan A, Choi J, Zavala L, Yost S, Hurria A. Association of Pre-Chemotherapy Peripheral Blood Pro-Inflammatory and Coagulation Factors with Reduced Relative Dose Intensity in Women with Breast Cancer. The Oncologist.  2017 Oct;22(10):1189-1196. PubMed [journal] PMID: 28559409, PMCID: PMC5634764
 
Yuan Y, Hurria A. et al. Association of Baseline Pro-Inflammatory (IL-6, CRP) and Coagulation (D-dimer) Markers with Baseline Functional Status in Women with Breast Cancer (BC) Undergoing Chemotherapy. Oncologist, 22 (10) 1189-1196. Oct 2017 doi: 10.1637/theoncologist.2016-0391 PMID: 28559409 PubMed [journal] PMCID: PMC563476
 
Yuan Y, Yost SE, Yuan YC, Solomon NM, Mambetsariev I, Pal S, Frankel P, Salgia R, Neuhausen SL, Mortimer J. Correction: Genomic Mutation-Driven Metastatic Breast Cancer Therapy: a Single Center Experience. Oncotarget. 2017 Sep 22;8(37):62817. PubMed [journal] PMID: 28977992, PMCID: PMC5617552.
 
Kanaya N, Somlo G, Wu J, Frankel P, Kai M, Liu X, Wu SV, Nguyen D, Chan N, Hsieh MY, Kirschenbaum M, Kruper L, Vito C, Badie B, Yim JH, Yuan Y, Hurria A, Peiguo C, Mortimer J, Chen S. Characterization of Patient-Derived Tumor Xenografts (PDXs) as Models for Estrogen Receptor Positive (ER+HER2- and ER+HER2+) Breast Cancers. The Journal of steroid biochemistry and molecular biology. 2017; 170:65-74. NIHMSID: NIHMS785187 PubMed [journal] PMID: 27154416, PMCID: PMC5094906
 
Yuan Y, Nilesh V., Sun C.L., Li D., Smith D., Mortimer J., Luu T., Somlo G., Waisman J., Chao J., Katheria V., Synold T., Tran V., Mi S., Levi A., Yost S., Arsenyan A, Choi J, Zavala L., Hurria A. Association of Pre-Chemotherapy Peripheral Blood Pro-Inflammatory (IL-6, CRP) and Coagulation (D-dimer) Markers with Chemotherapy Toxicity and Reduced Dose Intensity (RDI) in Women with Breast Cancer. SIOG 2016. Breast Cancer Res. 2017 Aug 29;19(1):101 doi: 10.1186/s13058-017-0895-5 PubMed [journal] PMID: 28851415 PMCID: PMC5576099
 
Yuan Y, Kos FJ, He TF, Yin HH, Li M, Hardwick N, Zurcher K., Schmolze D, Lee P, Pillai RK,  Chung V, Diamond DJ. Complete Regression of Cutaneous Metastases with Systemic Immune Response in a Patient with Triple Negative Breast Cancer Receiving p53MVA Vaccine with Pembrolizumab. Oncoimmunology. 2017 Aug 11;6(12). PubMed [journal] PMID: 29209571, PMCID: PMC5706612
 
Bitz C, Mortimer J, Kruper L, Waisman J, Clark K, Yuan Y, Vito C, Polamero E, Rodriguez J, Hernandez T, Loscalzo M. Couples Coping with Cancer Together: a Realistic Strengths-Based Strategic Program Integrated as the Standard of Medical Care for Breast Cancer. ISOP; 2017; c 00. My Bibliography [meeting]
 
Somlo G, Sierra M, Frankel PH, Schmolze D, Treece T, Mortimer JE, Waisman JR, Yuan Y, Yeon CH, Kruper L, Tumyan L, Taylor L, Yim JH, Van Der Baan B, Hurria A, Vito C. Gene Expression (GE) Profiles Associated with Pathologic Complete Response (pCR) in Locally Advanced and Inflammatory Triple Negative (TN) and HER+ (HER2+) Breast Cancer (BC) Pertuzumab (pert), Trastuzumab (trast), and Nab. ASCO; 2017; c 00. My Bibliography [meeting]
 
Afkhami M, Amanam I, Aoun PA, Schmolze D, Yost S, Frankel PH, Nguyen K, Wai Yu W, Luu TH, Yuan Y. Genomic Profiling of Metaplastic Breast Cancer: a Single Center Experience. ASCO; 2017; c 00. My Bibliography [meeting]
 
Mortimer JE, Yuan Y, Jung JJ, Stewart DB, Chung S, Koehler S, Cooper J, Kruper L, Wong L, Dadwal S. Infections Associated with the Addition of Pertuzumab to Trastuzumab-Based Chemotherapy. ASCO; 2017; c 00. My Bibliography [meeting]
 
Bitz C, Clark K, Mortimer J, Waisman J, Yuan Y, Helton S, Hernandez T, Polamero E, Loscalzo M. High Risk Couples Counseling for Metastatic Breast Cancer Patients and Partners Focused on Perception of Prognosis and Early Death Discussions.  American Psychosocial Oncology Society National Conference; 2017 February; c 00. My Bibliography [meeting]
 
Kauffmann RM, Goldstein L, Marcinkowski E, Somlo G, Yuan Y, Ituarte PH, Kruper L, Taylor L, Vito C. Predictors of Antiestrogen Recommendation in Women With Estrogen Receptor–Positive Ductal Carcinoma In Situ. Journal of the National Comprehensive Cancer Network. 2016 Sept;14(9): 1081-1090. PubMed [journal] PMID: 27587621
 
Kauffmann R, Marcinkowski E, Goldstein L, Somlo G, Yuan Y, Ituarte PH, Kruper L, Taylor L, Vito C. Predictors of Antiestrogen Recommendation in Women With Estrogen Receptor-Positive Ductal Carcinoma In Situ. Journal of National Comprehensive Cancer Network. 2016 Sep;14(9):1081-90. PubMed [journal] PMID: 27587621
 
Yuan Y, Yost SE, Yuan YC, Yim J, Solomon NM, Mambetsariev I, Pal S, Frankel P, Salgia R, Mortimer JE. The Impact of Genomic Mutations on Metastatic Breast Cancer Treatment: a Retrospective Clinical Trial. SABCS; 2016; c 00. My Bibliography [meeting]
 
Yuan Y, Frankel P, Synold T, Lee P, Yost S, Waisman J, Somlo G, Hurria A, Mortimer J.  A Phase II Trial of the Addition of Pembrolizumab to Letrozole and Palbociclib in Patients with Metastatic Estrogen Receptor Positive Breast Cancer who have Stable Disease on Letrozole and Palbociclib. SABCS; 2016; c 00. My Bibliography [meeting] DOI: 10.1158/1538-7445.SABCS16-OT2-01-03
 
Somlo G, Frankel P, Yeon C, Yuan Y, Yim J, Kruper L, Taylor L, Mortimer J, Jones V, Vito C, Tumyan L, Paz B, Hurria A, Li D, Gaal K, Tong T. Phase II Trial of Pertuzumab, Trastuzumab, and Non-Paclitaxel in Patients (pts) with HER2 Overexpressing (HER2+) Locally Advanced/Inflammatory Breast Cancer (LABC) or Untreated Stage IV Metastatic Breast Cancer (MBC). SABCS; 2016; c 00. My Bibliography [meeting] DOI: 10.1200/jco.2013.31.15_suppl.606 Journal of Clinical Oncology 31, no. 15_suppl (May 20 2013) 606-606. PMID: 23878115
 
Wu X, Yost S, Wang J, Liu Z, Yang Y, Goldstein L, Yuan Y. A Retrospective Pilot Study of Longitudinal Molecular Discordance of Primary Versus Recurrent Triple Negative Breast Cancer (TNBC). SABCS; 2016; c 00. My Bibliography [meeting] DOI: 10.1200/JCO.2016.34.15_suppl.e12558 Journal of Clinical Oncology 34, no. 15_suppl
 
Chen CH, Cheng CT, Yuan Y, Zhai J, Arif M, Fong LW, Wu R, Ann DK. Elevated MARCKS Phosphorylation Contributes to Unresponsiveness of Breast Cancer to Paclitaxel Treatment. Oncotarget. 2015; 6(17):15194-208. PubMed [journal] PMID: 26015406, PMCID: PMC4558145
 
Identification of Molecular Pathways to Define the Intake Rate of ER+ Paient-Derived Tumor Xenografts (PDXs) in NSG mice. Kanaya N, Somlo G, Frankel P, Wu J, Wu SV, Nguyen D, Kai M, Chan N, Hsieh MY, Kirchenbaum M, Kruper L, Vito C, Yuan Y, Hurria M, Mortimer J, Chen S. SABCS; 2015; c 00 . My Bibliography [meeting] DOI: 10.1158/1538-7445.SABCS15-P3-03-02
 
Marcinkowski E, Luu T, Yuan Y, Mortimer J, Leong L, Portnow J, Xing Q, Wen W, Yim JH. The Combination of Eribulin and Everolimus Results in Enhanced Suppression of Tumors in Mouse Models of Triple Negative Breast Cancer. . SABCS; 2015; c 00. My Bibliography [meeting] DOI: 10.1158/1538-7445.SABCS15-P6-13-17
 
Petrossian K, Lo C, Yuan Y, Chen S, Huang CS, Synold T, Kanaya N, Wu SV. Molecular Characterization of CDK 4/6 Inhibitors (Plabociclib, Abemaciclib, and Ribociclib) in Hormone Receptor-Positive Breast Cancer Cell Lines. . SABCS; 2015; c 00. My Bibliography [meeting] DOI: 10.1158/1538-7445. SABCS15-P5-03-07
 
Somlo G, Chung S, Frankel P, Hurria A, Koehler S, Kruper L, Mortimer JE, Paz B, Robinson K, Taylor L, Vito C, Waisman J, Yeon C, Yim J, Yuan Y, Tong T. Phase II Trial of Neoadjuvant Chemotherapy with Carboplatin and Nab-Paclitaxel in Patients with Triple Negative Locally Advanced and Inflammatory Breast Cancer. SABCS; 2015; c 00. My Bibliography [meeting] DOI: 10.1158/1538-7445.SABCS15-P1-14-10.
 
Yuan Y, Voral N, Hurria A.  Association of the Baseline Pro-Inflammatory (IL-6, CRP) and Coagulation (D-dimer) Markers with Relative Dose Intensity (RDI) in Women with Breast Cancer (BC) Undergoing (neo) Adjuvant Chemotherapy (chemo). Annual ASCO Meeting; 2015; c 00 . My Bibliography [meeting]
 
Skin, nail and staphylococcal infections associated with the addition of pertuzumab to trastuzumab-based chemotherapy. Yuan Y, Nilesh NL, Smith DD, Synold TW, Mortimer JE, Thenag LH, Somlo G, Waisman JR, Chao J, Levi A, Choi J, Katheria V, Tran V, Mi S, Zavala L, Hurria A. Annual ASCO Meeting; 2015; c 00 . My Bibliography [meeting] DOI: 10.1200/jco.2015.33.15_suppl.e11610 Journal of Clinical Oncology 33, no. 15_suppl (May 20 2015) 9539-9539.
 
Chen CH, Cheng CT, Yuan Y, Wu R, Ann D, Zhai, J. MARCKS Phosphorylation is Associated with Breast Cancer Malignancy and Paclitaxel Unresponsiveness.  Annual ASCO Meeting; 2015; c 00 . My Bibliography [meeting] DOI: 10.1200/jco.2015.33.15_suppl.e22007 Journal of Clinical Oncology 33, no. 15_suppl
 
Marcinkowski EF, Kauffmann RM, Ottesen R, Niland J, Yuan Y, Kruper L, Taylor L, Somlo G, Waisman J, Kim J, Vito C. Acceptance of Chemotherapy Recommendation in Patients with early-Stage Breast Cancer. Surgical of Surgical Oncology Annual Meeting; 2015 March; Houston, Texas. c 00 . My Bibliography [meeting]
 
Kauffmann R, Marcinkowski E, Goldstein L, Somlo G, Yuan Y, Ituarte P, Kruper L, Taylor L, Vito C. Society of Surgical Oncology Annual Meeting; 2015 March; Houston, Texas. c 00 . My Bibliography [meeting]
 
Mortimer JE, Yuan Y, Jung J, Kruper L, Stewart D, Chung S, Yu KW, D’Apuzzo M, Tegtmeier B, Dadwal S. Skin, and Nail Infections Associated with the Addition of Pertuzumab to Trastuzumab-Based Therapy. Breast Cancer Res Treat. 2014 Dec;148(3):563-70. PubMed [journal] PMID: 25385180 PMCID: PMC4243002
 
Khan S, Bennit HF, Turay D, Perez M, Mirshahidi S, Yuan Y, Wall NR. Early Diagnostic Value of Survivin and its Alternative Splice Variants in Breast Cancer. BMC Cancer. 2014 Mar 12; 14:176. PubMed [journal] PMID: 24620748, PMCID: PMC3995700
 
Yuan Y, Hurria A. Association of Baseline Pro-Inflammatory (IL-6, CRP) and Coagulation (D-dimer) Markers with Baseline Functional Status in Women with breast Cancer (BC) Undergoing Chemotherapy. SABCS; 2014; c 00. My Bibliography [meeting]
 
Mortimer JE, Yuan Y, Stewart D, Chung S, Kruper L, Wong LC, Mendelsohn M, Behrendt C, Dadwal S, Tegtmeier B. SABCS; 2014; c 00 .  My Bibliography [meeting]
In The News
An Expert's Voice
Yuan Yuan

A triple-negative breast cancer trial has its first success story

cancer cell

New hormone and immunotherapy trial for breast cancer patients

Yuan-Yuan

What Is Metastatic Triple-negative Breast Cancer?